Ocugen positive prelim AMD, GA gene therapy data

 Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). Key findings include: no drug-related serious adverse events, reduced lesion growth, preservation of retinal tissue, and—most importantly—there was a positive effect on the functional visual measure of low luminance visual acuity (LLVA).

https://www.globenewswire.com/news-release/2024/11/19/2983456/0/en/Ocugen-Announces-Compelling-Preliminary-Data-for-OCU410-a-Single-Dose-Novel-Modifier-Gene-Therapy-to-Treat-Geographic-Atrophy-Secondary-to-Dry-Age-Related-Macular-Degeneration.html